ICI 204,636: A new atypical antipsychotic drug

British Journal of Psychiatry

Volumn 168, Issue MAY SUPPL. 29, 1996, Pages 45-56

  Hirsch, Steven R ^a   Link, Christopher G G ^b   Goldstein, Jeffrey M ^b   Arvanitis, Lisa A ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; DOPAMINE; PROLACTIN; QUETIAPINE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

AGITATION; ARTICLE; DRUG RESEARCH; HEADACHE; INSOMNIA; MONKEY; NONHUMAN; PHARMACOLOGY; PHYSIOLOGY; RAT; REVIEW; RODENT; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; XEROSTOMIA; ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DYSKINESIA; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0029973862     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/s0007125000298310     Document Type: Article

References (28)

1. ALVIR, J. J., LIEBERMAN, J. A., SAFFERMAN, A. Z., et al (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the US. New England Journal of Medicine, 329, 162-167.
2. ARVANITIS, L. A., MILLER, B. G. & LINK, C. G. G. (1995) Seroquel™: an atypical antipsychotic agent. In Syllabus & Proceedings Summary of the 148th Annual Meeting of the American Psychiatric Association; May 23, 1995, abstract N32. Washington, DC: APA.
3. BLOOM, F. E. & KUPFER, D. J. (1994) Psychopharmacology, The Fourth Generation of Progress. New York: Raven Press.
4. BORISON, R. L., ARVANITIS, L. A., MILLER, B. G., et al (1995) Seroquel (ICI 204,636): a novel atypical antipsychotic (abstract N243). Presented at the 50th Annual Meeting of the Society of Biological Psychiatry; May 20, 1995. Biological Psychiatry, 37, 661.
5. _, _, _, et al (1996) Multicenter, placebo-controlled, double-blind safety and efficacy evaluation of ICI 204,636 in hospitalized patients with acute exacerbation of chronic or subchronic schizophrenia. Journal of Clinical Psychopharmacology, 16, 158-169.
6. FABRE, L. F., ARVANITIS, L., PULTZ, J., et al (1995) ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clinical Therapeutics, 17, 366-378.
7. GOLDSTEIN, J. M. (1995a) Pre-clinical pharmacology of new atypical antipsychotics in late stage development. Expert Opinion on Investigational Drugs, 4, 291-298.
8. _ (1995b) ICI 204,636 (Seroquel™): new preclinical research data confirm atypical antipsychotic actions. In New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association; May 24, 1995 poster NR461. Washington, DC: APA.
9. _, LITWIN, L. C., SUTTON, E. B., et al (1993) Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology, 112, 293-298.
10. _ & SNYDER, D. H. (1995) Effects of Seroquel™ and other atypical antipsychotics in primate models of EPS (abstract 193). Presented at the 50th Annual Meeting of the Society of Biological Psychiatry; May 19, 1995. Biological Psychiatry, 37, 646.
11. GRACE, A. A. & BUNNEY, B. S. (1995) Electrophysiological properties of midbrain dopamine neurons. In Psychopharmacology, the Fourth Generation of Progress (eds F. E. Bloom & D. J. Kupfer), pp. 162-177. New York: Raven Press.
12. HAMNER, M. B., ARVANITIS, L. A., MILLER, B. G., et al (1995a) Lack of sustained elevation of plasma prolactin in schizophrenic patients treated with ICI 204,636 (Seroquel™). In New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association; May 23, 1995, poster NR200. Washington, DC: APA.
13. _, _, _, et al (1995b) The effects of Seroquel (ICI 204,636) on plasma prolactin in patients with schizophrenia (abstract 322). Presented at the 50th Annual Meeting of the Society of Biological Psychiatry; May 20, 1995. Biological Psychiatry, 37, 683.
14. HARING, C., NEUDORFER, C., SCHWITZER, J., et al (1994) EEG alterations in patients treated with clozapine in relation to plasma levels. Psychopharmacology, 114, 97-100.
15. HIRSCH, S. R. (1994) Seroquel: an example of an atypical antipsychotic drug (abstract). Neuropsychopharmacology, 10 (suppl. 1), 371S.
16. _, ARVANITIS, L., MILLER, B., et al (1994) A multicentre, double-blind, placebo-controlled comparison of low and high dosage regimens of Seroquel in the treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia (abstract). European Neuropsychopharmacology, 4, 384-385.
17. HUANG, M. L., VAN, P. A., WOESTENBORGHS, R., et al (1993) Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy volunteers. Clinical Pharmacology and Therapeutics, 54, 257-268.
18. LIEBERMAN, J. A. (1993) Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in development. British Journal of Psychiatry, 22 (suppl. 22), 7-18.
19. LINK, C., ARVANITIS, L. A., MILLER, B., et al (1994a) A multicentre, placebo-controlled, double-blind evaluation of Seroquel in hospitalised patients with acute exacerbation of chronic and subchronic schizophrenia (abstract). European Neuropsychopharmacology, 4, 385-386.
20. _, SMITH, A., MILLER, B., et al (1994b) A multicentre, double-blind, controlled comparison of Seroquel and chlorpromazine in the treatment of hospitalised patients with acute exacerbation of subchronic and chronic schizophrenia (abstract). European Neuropsychopharmacology, 4, 385.
21. MELTZER, H. Y. (1995) Atypical antipsychotic drugs. In Psychopharmacology, the Fourth Generation of Progress (eds F. E. Bloom & D. J. Kupfer), pp. 1277-1286. New York: Raven Press
22. _, MATSUBARA, S. & LEE, J.-C. (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin-2 pKi values. Journal of Pharmacology and Experimental Therapeutics, 251, 238-246.
23. _, HIRSCH, S. R., ARVANITIS, L. A., et al (1996) ICI 204,636, an atypical antipsychotic: an open-label, international, multicenter trial of efficacy and safety in patients with acute psychotic symptoms.
24. MIGLER, B. M., WARAWA, E. J. & MALICK, J. B. (1993) Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology 112, 299-307.
25. SALLER, C. F. & SALAMA, A. I. (1993) Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology, 112, 285-292.
26. SIMPSOM, G. M. (1976) Neurological Rating Scale. In ECDEU Assessment Manual for Psychopharmacology (Revised 1976) (ed. W Guy). Rockville, Maryland: US Dept. Of Health, Education and Welfare, NIMH.
27. _ & ANGUS, J. W. S. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, 212 (suppl. 44), 11-19.
28. SMALL, J. G., HIRSCH, S. R., ARVANITIS, L. A., et al (1996) The efficacy and safety of ICI 204,636 (Seroquel™) in patients with schizophrenia: high- and low-dose, double-blind comparison with placebo.